Laffen v. Hewlett-Packard Company, Plan Committee Investment Review Committee et al
Filing
143
ORDER by Judge Charles R. Breyer granting 125 Motion to Dismiss (crblc2, COURT STAFF) (Filed on 6/15/2015)
1
2
3
4
5
6
7
8
9
IN THE UNITED STATES DISTRICT COURT
FOR THE NORTHERN DISTRICT OF CALIFORNIA
United States District Court
For the Northern District of California
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
IN RE HP ERISA LITIGATION
No. 3:12- cv-06199-CRB
/
ORDER GRANTING MOTION TO
DISMISS SECOND AMENDED
COMPLAINT
Among the extensive litigation spawned by Defendant Hewlett-Packard Company’s
(“HP”) failed acquisition of Autonomy Inc. is a putative ERISA class action alleging that
various investment managers and HP executives breached their fiduciary duties by failing to
disclose material information about the problems with Autonomy. On April 2, 2014, this
Court granted a motion to dismiss the First Amended Complaint (“FAC”) on the grounds that
a presumption of prudence applies and that it was not improper for Defendants to take the
time to investigate prior to making any disclosures. See Order re FAC (dkt. 116).
According to Plaintiffs, two relevant events have occurred since this Court dismissed
the FAC that can save their amended complaint. First, two Financial Times (“FT”) articles
supposedly brought to light new facts that could remedy the FAC’s pleading defects. And
second, the Supreme Court decided Fifth Third Bancorp v. Dudenhoeffer, 134 S. Ct. 2459
(2014), which abrogated the presumption of prudence and articulated pleading standards for
this precise type of claim. Plaintiffs filed a Second Amended Complaint (“SAC”), which
pares down the lengthy claims of its predecessor to a single count that tracks the language of
Fifth Third and a Ninth Circuit case that applied it, Harris v. Amgen, 770 F.3d 865 (9th Cir.
1
2014). Defendants now move to dismiss the SAC. Mot. Dismiss (dkt. 125). Because
2
Plaintiffs have failed to allege facts sufficient to state a claim, the Court hereby GRANTS the
3
motion to dismiss the SAC.
4
I.
5
BACKGROUND
The details of HP’s acquisition of Autonomy have been detailed at length in prior
6
orders and are not repeated here. However, because this suit was filed under The Employee
7
Retirement Income Security Act of 1974, 29 U.S.C. §§ 1001-1461 (“ERISA”), background
8
information on HP’s retirement plan and the specific ERISA allegations is relevant.
9
United States District Court
For the Northern District of California
10
A.
The Plan
The SAC alleges the following facts. HP sponsors a 401(k) retirement plan (the
11
“Plan”) for its employees. SAC ¶ 39. The Plan is governed by the HP Company 401(k)
12
Savings Plan, as amended and restated as of January 1, 2007, and January 1, 2012 (the “Plan
13
Document”). Id. ¶ 49. The Plan Document identifies and names two fiduciaries for the Plan:
14
the Plan Committee for operation and administration of the Plan, and the Investment Review
15
Committee (“IRC”) for control and management of the assets of the Plan. Id. ¶¶ 46, 49.
16
Each of the named individual defendants was a member of the IRC while employed by HP
17
during the class period. Id. ¶¶ 32–36.
18
HP is the Plan’s nominal sponsor. Id. ¶ 26. However, HP appointed State Street Bank
19
and Trust Company to serve as the investment manager for the HP Common Stock Fund. Id.
20
¶¶ 37–38. State Street was the “investment manager and independent fiduciary” with
21
authority, discretion, and control regarding the HP Common Stock Fund under the Plan. Id.
22
¶¶ 38, 53. The Plan Document limits the level of discretion that the Plan Committee and the
23
IRC have with respect to the management of the HP Common Stock Fund. Id. ¶ 50.
24
The Plan is a contribution benefit plan open to all HP employees. Id. ¶ 39. Plan
25
participants have the option of making voluntary contributions to their accounts which HP
26
matches dollar-for-dollar up to the first four percent of a participant’s eligible compensation.
27
Id. ¶ 40. Plan participants freely decide how to allocate and reallocate their contributions,
28
and HP’s matching contributions, in a variety of offerings which the Plan Document divides
2
1
into two categories: Investment Funds1 and the dedicated HP Common Stock Fund (the “HP
2
Fund”). Id. ¶ 41.
3
This lawsuit focuses on the HP Fund. The HP Fund is an employee stock ownership
4
plan (“ESOP”) which, under ERISA, is required to invest exclusively in HP stock.2 See SAC
5
¶ 65. As an ESOP, the HP Fund, consistent with the intent of Congress in enacting ERISA,
6
provides a simple way for HP employees to invest directly in the company for which they
7
work. See Quan v. Computer Sciences Corp., 623 F.3d 870, 879 n.7 (9th Cir. 2010) (noting
8
that Congress intended for ESOPs “to reward and motivate employees by making them
9
stakeholders in the success of the companies that employ them”), abrogated on other grounds
United States District Court
For the Northern District of California
10
by Fifth Third, 134 S. Ct. 2459. Though ERISA requires that this ESOP invest exclusively
11
in HP stock, the Plan Document gives broad discretion to the Trustee regarding the “time,
12
price, amount and manner of purchase of Stock for the Stock Fund.” Conway Decl., Ex. A at
13
§ 9(b) (401(k) Savings Plan, dkt. 82-1).3
14
B.
15
Plaintiffs are former HP employees and participants in HP’s 401(k) Stock Fund. SAC
The Parties
16
¶¶ 20–22. Plaintiffs purchased HP stock through the Plan during the Class Period. Id.
17
Plaintiffs allege that they suffered losses from purchasing and holding HP stock, rather than
18
purchasing or diversifying into other investment options under the Plan. Id. ¶¶ 20–22, 70.
19
The SAC alleges that non-party State Street Bank and Trust company (“State Street”)
20
is a trust company independent from HP that HP appointed to serve as the investment
21
manager for the HP Fund during the class period. Id. ¶¶ 37–38. Plaintiffs allege that State
22
Street acted as a co-fiduciary and independent investment manager with authority, discretion
23
In 2012, the IRC permitted investment in 27 funds in addition to the HP Stock Fund, including
money market funds, bond funds, and mutual funds offered through Fidelity Investments. Conway
Decl., Ex. C at 25–27.
1
24
25
The parties agree that to qualify as an ESOP the HP Stock Fund is required to invest
exclusively in HP Stock. Compare Mot. to Dismiss FAC (dkt. 81) at 2, with Opp’n to Mot. to Dismiss
FAC (dkt. 98) at 7. They dispute whether the Plan required that the HP Stock Fund be available as an
investment option.
2
26
27
28
The Court granted the unopposed motion to take judicial notice of these documents in its
Order granting the motion to dismiss the FAC. Order at 1.
3
3
1
and control regarding the offering, and continued offering, of the HP Fund under the
2
Plan—subject to the oversight and supervision of the IRC. Id. ¶ 38. State Street “ha[d] no
3
discretion as to whether to continue the availability of [the HP Stock] Fund as an investment
4
option.” Conway Decl., Ex. G at 1 (dkt. 82-7).
5
Defendant Catherine A. Lesjak was HP’s Chief Financial Officer during the Class
6
Period and the Chair of the IRC. SAC ¶ 32. Defendant John N. McMullen was HP’s
7
Treasurer during the Class Period. Id. ¶ 33. Defendant James T. Murrin was HP’s Controller
8
from the start of the Class Period until March 2012. Id. ¶ 34. Defendant Mark A. Levine
9
was HP’s Controller from March 2012 through the end of the Class Period. Id. ¶ 35.
United States District Court
For the Northern District of California
10
Defendants Lesjak, McMullen, Murrin, and Levine were named fiduciaries under the Plan.
11
Id. ¶¶ 32–38. Defendants McMullen, Murrin, and Levine were also members of the Plan
12
Committee. Id. ¶ 36.
13
C.
14
The SAC alleges, in essence, that Defendants violated their fiduciary duties under
ERISA Allegations
15
ERISA by engaging in an illegal scheme to conceal material facts about Autonomy’s
16
improper accounting practices in that they failed to freeze new investments in the HP Stock
17
Fund and/or failed to disclose complete and accurate information to Plan participants despite
18
knowing that HP stock had become artificially inflated in value. See, e.g., SAC ¶ 135. The
19
SAC alleges that Defendants did so despite “ha[ving] the authority and discretion to cease
20
the continued offering of the HP Common Stock Fund, to restrict or suspend investments or
21
to eliminate or sell out.” Id. ¶ 61.
22
The Autonomy acquisition officially closed on October 3, 2011, at a purchase price of
23
$11.1 billion. Id. ¶¶ 73–74. At that point, HP began to integrate Autonomy, and the SAC
24
alleges that “[a]lmost immediately, HP’s senior management became aware of HP’s
25
improper accounting practices. Id. ¶¶ 75–76. But the facts alleged in support of any such
26
discovery are thin. The SAC focused on two of Autonomy’s improper accounting practices
27
that allegedly came to HP’s attention immediately after the acquisition. First, one of
28
Autonomy’s frauds was later determined to involve the use of loss-making hardware sales to
4
1
make up for revenue shortfalls in software sales. Id. ¶ 77. The SAC alleges that a February
2
17, 2014, FT article states that several emails show that HP executives, perhaps including
3
Meg Whitman, “were included in communications that referred to hardware sales” by
4
Autonomy. Id. ¶ 77–78. And, Deloitte work papers that were available to HP to review once
5
the acquisition closed stated that “hardware accounted for 9 per cent of Autonomy’s sales in
6
the previous six months.” Id. ¶ 79. As to this point, the SAC concludes that “it is reasonable
7
to infer that the senior-most financial officers at HP . . . would have been aware of these facts
8
[on October 3, 2011]” and would have understood the implications of this information with
9
respect the accuracy of Autonomy’s accounting practices.” Id. ¶ 80.
United States District Court
For the Northern District of California
10
Second, the SAC alleges that HP was aware soon after the acquisition closed that
11
Autonomy was booking software sales to retailers. Id. ¶ 81. The SAC alleges that this
12
practice was acceptable under international accounting rules but ran afoul of United States
13
accounting rules, and that the FT article states this was known to HP senior management at
14
the time the acquisition closed. Id. ¶ 81. Again, the SAC concludes that “it is reasonable to
15
infer” that senior management would have known about “a major discrepancy in accounting
16
practice” and “would have understood the implications of this information.” Id. ¶ 81.
17
The SAC goes on to allege that “[r]ather than come clean about what it had learned
18
about Autonomy’s accounting practices . . . HP attempted to ‘unwind’ these accounting
19
improprieties in secret.” Id. ¶ 84. After the acquisition closed, HP undertook a series of
20
studies of Autonomy’s software sales, including one by HP Worldwide Director of Software
21
Revenue Recognition Paul Curtis, one by HP’s auditor E&Y in connection with HP’s year-
22
end audit, and one by E&Y and KPMG in order to optimize Autonomy’s revenue procedures
23
for United States accounting standards. Id. ¶ 86. The SAC concludes that it is “reasonable to
24
infer that senior-level financial and accounting executives” would have been appraised of
25
what the investigations revealed and “would have understood what it meant.” Id. ¶ 87. HP’s
26
deteriorating license revenue growth and software operating margin after the Autonomy
27
acquisition allegedly indicate that “HP had begun a gradual winddown of Autonomy’s
28
improper accounting practices.” Id. ¶¶ 88–91.
5
1
HP’s quiet efforts to remedy Autonomy’s accounting practices were allegedly
2
“upended” by the whistleblower allegations that emerged in May 2012. Id. ¶ 93. HP then
3
initiated an investigation by Pricewaterhouse Coopers (“PwC”)—but this was “little more
4
than theater . . . considering that the accounting improprieties revealed to HP by the
5
whistleblower were already well known to it,” as evidenced by the FT’s disclosure that “HP
6
executives routinely discussed Autonomy hardware sales months before the supposed
7
whistleblower came forward.” Id. ¶¶ 93–94. Senior Autonomy executive Michael Lynch
8
left HP soon after the whistleblower allegations, and later insisted that Autonomy was “fully
9
open and transparent with its auditors” all along. Id. ¶¶ 96–98.
United States District Court
For the Northern District of California
10
In the following months, while the PwC investigation continued, “the Autonomy
11
business at HP reported worse and worse results,” including an announcement on August 8,
12
2013, that HP would take an $8 billion goodwill impairment charge within its Services
13
segment. Id. ¶ 100–103. On November 20, 2012, six months after the whistleblower came
14
forward, HP announced it would write down 85% of Autonomy’s purchase price, over $5
15
billion of which was due to Autonomy’s serious accounting improprieties and fraud. Id.
16
¶ 104. HP’s stock declined 12% on this news. Id. ¶ 106. Specifically, HP’s stock price fell
17
from $13.30 to $11.71, only to bounce back within 9 trading days and not close below that
18
level since—indeed, HP’s stock price has nearly tripled since November 19, 2012, the day
19
before HP disclosed an Autonomy fraud. Mot. Dismiss at 16.
20
The SAC alleges that on these facts, Defendants breached their fiduciary duties by
21
taking no corrective “action to protect the Plan or its participants from foreseeable harm and
22
damage” despite knowing that “HP’s stock had become artificially overvalued and far riskier
23
than Plan participants could have known” and would “suffer from a substantial correction”
24
when Autonomy’s accounting practices came to light. SAC ¶¶ 111–12. Specifically, the
25
SAC alleges that “Plan Fiduciaries could have provided new investment guidelines to State
26
Street halting all new purchases of HP stock” and could have made public disclosures about
27
HP’s knowledge of Autonomy’s accounting improprieties. Id. ¶ 113. The SAC concludes
28
that no fiduciary in Defendants’ positions could reasonably have concluded that “doing
6
1
nothing would be less harmful to Plan participants than taking either or both” of the
2
suggested actions because “a stock price always falls when news of a fraud is revealed.” Id.
3
¶ 114.
4
D.
5
On November 26, 2013, this Court ruled on motions to dismiss in a related securities
This Court’s Ruling in the Related Securities Litigation
6
litigation case based on the same underlying facts. In re HP Securities Litigation, No. 12-
7
5980 (dkt. 201) (“Securities Order”). This Securities Order granted in part and denied in part
8
the motions to dismiss. Specifically, the Court rejected all claims involving statements made
9
prior to May 23, 2012, and all claims regarding statements made by Lesjak. Id. However,
United States District Court
For the Northern District of California
10
the Court assumed, without deciding, the falsity of the statements at issue because its “ruling
11
hinge[d] primarily on the issue of scienter.” Id. at 8. The parties have since reached a
12
settlement in that action, which awaits approval by this Court. See Mot. Settlement (No. 12-
13
5980, dkt. 257).
14
II.
15
LEGAL STANDARD
Pursuant to Federal Rule of Civil Procedure 12(b)(6), a complaint may be dismissed
16
for failure to state a claim upon which relief may be granted. Dismissal may be based on
17
either “the lack of a cognizable legal theory or the absence of sufficient facts alleged under a
18
cognizable legal theory.” Balistreri v. Pacifica Police Dep’t, 901 F.2d 696, 699 (9th Cir.
19
1990). For purposes of evaluating a motion to dismiss, a Court “must presume all factual
20
allegations of the complaint to be true and draw all reasonable inferences in favor of the
21
nonmoving party.” Usher v. City of Los Angeles, 828 F.2d 556, 561 (9th Cir. 1987). A
22
complaint must plead “enough facts to state a claim to relief that is plausible on its face.”
23
Ashcroft v. Iqbal, 129 S. Ct. 1937, 1949 (2009) (citing Bell Atlantic Corp. v. Twombly, 550
24
U.S. 544, 570 (2007)). A claim is plausible “when the plaintiff pleads factual content that
25
allows the court to draw the reasonable inference that the defendant is liable for the
26
misconduct alleged.” Id.
27
28
The claims for breach of fiduciary duty that Plaintiffs assert are governed by ERISA,
which requires fiduciaries of retirement plans to “discharge [their] duties with respect to a
7
1
plan solely in the interest of the participants and beneficiaries” and to do so “with the care,
2
skill, prudence, and diligence under the circumstances then prevailing that a prudent man
3
acting in a like capacity and familiar with such matters would use in the conduct of an
4
enterprise of a like character and with like aims.” 29 U.S.C. § 1104(a)(1).
Claims for fraud must meet the pleading standard of Federal Rule of Civil Procedure
5
6
9(b), which requires a party “alleging fraud or mistake [to] state with particularity the
7
circumstances constituting fraud or mistake.” Fed. R. Civ. P. 9(b). Rule 9(b) “requires an
8
account of the time, place, and specific content of the false representations as well as the
9
identities of the parties to the misrepresentations.” Swartz v. KPMG LLP, 476 F.3d 756, 764
United States District Court
For the Northern District of California
10
(9th Cir. 2007) (internal quotation marks omitted).
11
III.
DISCUSSION
12
The instant motion to dismiss calls this Court to determine how, if at all, the Court’s
13
previous Order dismissing the FAC has been affected by new facts from the FT articles and
14
by new law from Fifth Third and Harris. Looking at the legal sufficiency of the allegations
15
in toto in light of the aforementioned case law and factual developments, the Court GRANTS
16
the motion to dismiss the SAC. The “new facts” from the FT articles show nothing more
17
than that HP knew around the time of the acquisition that Autonomy sold hardware and used
18
value-added resellers—not that Autonomy engaged in fraud in its accounting or use of these
19
practices. At most, the FT articles insinuate that there was no Autonomy fraud at all—rather,
20
that HP was mistaken in its valuation of Autonomy and botched the integration, and in
21
hindsight seeks to shift the blame for its own incompetence. Whatever the import of that
22
scenario for a different lawsuit, it provides no support for—indeed, undermines—the claims
23
at issue in this ERISA suit that HP concealed a fraud from investors. Ultimately, the SAC
24
fails to state a claim that HP was imprudent under “the circumstances prevailing at the time”
25
HP acted, and accordingly must be dismissed. See Fifth Third, 134 S. Ct. at 2471 (quoting
26
§ 1104(a)(1)(B) (alternations omitted).
27
A.
28
In dismissing the FAC, this Court made several determinations relevant to the instant
The Court’s Order Dismissing the FAC
8
1
motion. First, the Court held that the Moench presumption of prudence applies, and
2
therefore, “to overcome the presumption of prudent investment, plaintiffs must . . . make
3
allegations that clearly implicate the company’s viability as an ongoing concern or show a
4
precipitous decline in the employer’s stock . . . combined with evidence that the company is
5
on the brink of collapse or is undergoing serious mismanagement. Order re FAC at 9 (citing
6
Moench v. Robertson, 62 F.3d 553, 571 (3d. Cir. 1995)). Plaintiffs having made no such
7
allegations, the Court granted the motion to dismiss the prudence claims. Id.
8
9
As to the disclosure claims, the Court noted that all of defendants’ statements and
omissions were made either before Whistleblower No. 4 came forward, or while the
United States District Court
For the Northern District of California
10
investigation into Whistleblower No. 4’s allegations was ongoing. Order re FAC at 9. The
11
Court held that the reasoning of its Securities Order in the parallel action was persuasive
12
here, in that it was “both proper and lawful” for HP to take the time necessary to investigate
13
the allegations because “[m]anagers cannot tell lies but are entitled to investigate for a
14
reasonable time, until they have a full story to reveal,” and defendants were under “no
15
obligation to prematurely report allegations, even if well founded[,] nor would Defendants
16
have been able to accurately determine the true amount of the required write-down absent a
17
thorough investigation.” Order re FAC at 10 (quoting Securities Order, 12-5980 (dkt.201) at
18
17). The Court also noted that “[i]f Defendants had been able to terminate or suspend the HP
19
Stock Fund as a result of concerns over Autonomy, the impact of such a termination or
20
suspension on the price of HP stock, including that already owned by the HP Stock Fund,
21
likely would have been dire.” Order re FAC at 10–11.
22
B.
23
Plaintiffs identify SAC ¶¶ 3, 77–79, 81, and 94–95 as containing the “new facts”
New Factual Allegations in the SAC
24
regarding Defendants’ alleged discovery of accounting improprieties at Autonomy. Opp.
25
(dkt. 131) at 22. The only “new facts” alleged in each of these paragraphs relate to the two
26
FT articles about the Autonomy acquisition. To the extent the SAC takes lines out of
27
context, the Court is entitled to look to the articles themselves to determine the plausibility of
28
the allegations. See Sprewell v. Golden State Warriors, 266 F.3d 979, 988 (9th Cir.),
9
1
amended on other grounds by 275 F.3d 1187 (9th Cir. 2001). The articles state that “HP was
2
put on notice about the existence of hardware sales at Autonomy in the seven months
3
between when it closed the deal and May 2012, when it says its attention was first drawn to
4
the transactions by a whistleblower.” Wolinsky Decl. (dkt. 126) Ex. 1, at 2 (FT Feb. 17,
5
2014). The article adds that “large sales of hardware were routinely acknowledged in
6
Autonomy audit reports” that “were available to HP management after the acquisition,” and
7
gives examples of emails between November 2011 and May 2012 that referred to hardware
8
sales.
But the Court does not understand Plaintiffs’ allegation to be that it was secret or
9
United States District Court
For the Northern District of California
10
improper for a software company to sell hardware bundles. Rather, as the FT article also
11
notes, HP has stated that it knew that “a portion of Autonomy’s revenues were related to
12
hardware sales,” but “knew nothing of the accounting improprieties, misrepresentations and
13
disclosure failures related to such sales” until Whistleblower No. 4 came forward. Id. at 2.
14
Along this same vein, the SAC makes much of the fact that the audit reports disclosed early
15
on that “hardware accounted for 9 per cent of Autonomy’s sales in the previous six
16
months—only slightly less than the 10-15 per cent HP later claimed was an indication of the
17
scale of the alleged misrepresentation.” But on the plain text of the article, the statement is
18
only that 9 or 10 or 15 percent of Autonomy’s revenue being fraudulent is a fraud on a
19
substantial “scale”—in other words, a relatively large fraud. But nothing indicates
20
knowledge of the fraud, as opposed to knowledge of the source of revenue, in an audit report
21
that merely says that 9% of sales came from hardware.
A similar pattern plays out with respect to the FT’s other alleged “revelation”: that HP
22
23
knew soon after the acquisition that Autonomy was recording sales to resellers in a way that
24
was permitted by international accounting rules, and that HP was making adjustments to
25
Autonomy’s approach to reflect US accounting rules. Id. at 3. But again, no one alleges that
26
sales to resellers in and of themselves are fraudulent. In other words, knowing about the
27
sales does not indicate that HP knew about the fraud, and the FT articles provides nothing
28
more.
10
1
In other words, there appears to be a disconnect between the SAC’s allegations and
2
the substance of the articles, even reading them in the light most favorable to the Plaintiffs.
3
The articles themselves doubt that Autonomy defrauded HP at all, and suggest instead that
4
HP merely made a bad investment—“overpaid for Autonomy, then botched its
5
integration”—and now seeks to shift the blame. Wolinsky Decl. Ex. 2, at 1 (FT Feb. 17,
6
2014). Thus, the FT’s evidence is meant to show that HP knew early on that Autonomy sold
7
hardware and made sales to resellers, but that “compelling corroboration has yet to emerge”
8
that any of those sales were fraudulent. Id. Both in light of this ultimate conclusion and
9
under a careful reading of the articles’ facts, the FT—and therefore the SAC’s “new
United States District Court
For the Northern District of California
10
evidence” to overcome this Court’s earlier holding—adds little or nothing to the facial
11
plausibility of Plaintiffs’ theory as a matter of pleading.
12
C.
13
The Supreme Court decided Fifth Third Bancorp v. Dudenhoeffer, 134 S. Ct. 2459
Fifth Third and Harris
14
(2014), shortly after this Court issued its Order granting the motion to dismiss the FAC—and
15
thus that Order’s reliance on the Moench presumption of prudence became short-lived. See
16
Moench, 62 F.3d at 571; Quan, 623 F.3d at 882. In Fifth Third, the Supreme Court held that
17
an ESOP fiduciary’s decision to buy or hold the employer’s stock is subject to the same duty
18
of prudence that applies to ERISA fiduciaries in general,4 except that the fiduciary need not
19
diversify the fund’s assets. 134 S. Ct. at 2467. In so doing, the Court abrogated the Moench
20
presumption of prudence that had previously set a higher standard of pleading for this type of
21
claim. Id.
22
The allegations at issue in Fifth Third, like those here, claimed that “nonpublic
23
information (which petitioners knew because they were Fifth Third insiders) indicated that
24
Fifth Third officers had deceived the market by making material misstatements about the
25
company’s financial prospects,” which artificially inflated the price of Fifth Third stock. Id.
26
at 2464. The Court articulated the following pleading requirement for this type of claim:
27
28
That standard asks what a prudent person would do “‘in the conduct of an enterprise of a like
character and with like aims.’” 134 S. Ct. at 2463 (quoting § 1104(a)(1)(B)).
4
11
1
2
3
4
5
6
7
8
9
United States District Court
For the Northern District of California
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
To state a claim for breach of the duty of prudence on the basis of inside information,
a plaintiff must plausibly allege an alternative action that the defendant could have
taken that would have been consistent with the securities laws and that a prudent
fiduciary in the same circumstances would not have viewed as more likely to harm the
fund that to help it.
Id. at 2472. “[T]hree points inform the requisite analysis.” Id. First, “the duty of prudence
. . . does not require a fiduciary to break the law,” including insider trading laws, so
“ERISA’s duty of prudence cannot require an ESOP fiduciary” to sell the fund’s stock on the
basis of inside information. Id. at 2472–73. The second point arises where, as here, “a
complaint faults fiduciaries for failing to decide, on the basis of the inside information, to
refrain from making additional stock purchases or for failing to disclose that information to
the public so the stock would no longer be overvalued.” See id. at 2473. In these
circumstances, the “courts should consider the extent to which an ERISA-based obligation
either to refrain on the basis of inside information from making a planned trade or to disclose
inside information to the public could conflict with the complex insider trading and corporate
disclosure requirements imposed by the federal securities laws or with the objectives of those
laws.” Id. at 2473 (citing 29 U.S.C. § 1144(d) (“Nothing in this subchapter [which includes
§ 1104] shall be construed to alter, amend, modify, invalidate, impair, or supersede any law
of the United States . . . or any rule or regulation issued under any such law.”).
The SAC does not allege facts sufficient to plead the two main elements under Fifth
Third. First, “a plaintiff must plausibly allege an alternative action that the defendant could
have taken that would have been consistent with the securities laws.” 134 S. Ct. at 2472.
The alternative actions that the SAC alleges are “restricting transactions or new investments
by the Plan in HP Stock and/or” publicly disclosing its “illegal scheme to hide or conceal
material adverse facts about Autonomy’s improper accounting practices.” SAC ¶ 135. But it
is inconsistent with, or at least “alters,” the disclosure regime of the securities laws to require
HP to disclose in real time any suspicions or allegations about Autonomy that are yet
uninvestigated. See, e.g., In re Boston Scientific Corp. Sec. Litig., 686 F.3d 21, 27–28 (1st
Cir. 2012) (Securities laws do not require a company “to disclose immediately all
information that might conceivably affect stock prices”; such a rule “would be extreme” and
12
1
“could easily disadvantage shareholders in numerous ways . . . .”); Matrixx Initiatives, Inc. v.
2
Siracusano, 131 S. Ct. 1309, 1321 (2011) (“[Section] 10(b) and Rule 10b-5(b) do not create
3
an affirmative duty to disclose any and all material information” that a company possesses).
4
This Court already held that under these circumstances, it was proper for HP to investigate
5
Whistleblower No. 4’s allegations rather than spooking the market with half-baked
6
allegations. Fifth Third directs this Court to consider the extent to which a disclosure “could
7
conflict with the complex insider trading and corporate disclosure requirements . . . or with
8
the objectives of those laws,” 134 S. Ct. at 2473, and no laws envision the real-time
9
disclosure that Plaintiffs demand here.
United States District Court
For the Northern District of California
10
Second, the SAC fails to allege facts that make it plausible that “a prudent fiduciary in
11
the same circumstances would not have viewed” pre-investigation disclosure to be “more
12
likely to harm the fund that to help it”—in other words, “that a prudent fiduciary in the
13
defendant[s’] position could not have concluded that . . . publicly disclosing negative
14
information would do more harm than good to the fund by causing a drop in the stock price
15
and a concomitant drop in the value of the stock already held by the fund.” 134 S. Ct. at
16
2472, 2473. HP was entitled to investigate—indeed, there is little doubt that HP would have
17
been subject to claims of imprudence had it disclosed uninvestigated allegations. See, e.g.,
18
Higginbotham v. Baxter Int’l, Inc., 495 F.3d 753, 760–61 (“Prudent managers conduct
19
inquiries rather than jump the gun with half-formed stories as soon as a problem comes to
20
their attention.”). As this Court already explained, the market impact of freezing the HP
21
Fund as a result of concerns over Autonomy “likely would have been dire,” and a prudent
22
manager could have—likely, would have, under the circumstances here—waited to
23
investigate the existence and extent of a third-party fraud before disclosing it to the market.
24
And no alleged facts establish that the six-month duration of the PwC investigation was itself
25
imprudent.
26
The only Ninth Circuit case to have yet applied Fifth Third in detail is Harris v.
27
28
13
1
Amgen, No. 10-56014, 2015 WL 3372373, -- F. 3d --, (9th Cir. May 26, 2015).5 There, the
2
Ninth Circuit reversed a district court’s dismissal of an ERISA complaint that alleged, like
3
the complaint we presently review, that defendants violated their duty of prudence by
4
continuing to provide the Amgen Common Stock Fund as an investment alternative when
5
they knew or should have known that the stock was being sold at an artificially inflated price.
6
Id. at *26, *44. The Ninth Circuit found it plausible under the circumstances of that case that
7
defendants could have removed the Amgen Stock Fund from the list of investment options
8
without causing undue harm to plan participants because“any reduction in the stock price
9
would anticipate (and only partially) the inevitable result of Amgen’s eventual compliance
United States District Court
For the Northern District of California
10
with the federal securities laws,” and because disclosure at the point at which fiduciaries
11
“knew or should have known that material information was being withheld from the public”
12
could prevent plan participants from making “continued investments in the fund at
13
increasingly inflated prices.” Id. at *46–47.
But Harris v. Amgen is fundamentally different from the instant case. In Amgen, the
14
15
alleged fraud was committed by Amgen officials themselves. In other words, the facts
16
involved an alleged fraud perpetrated by Amgen itself in which Amgen made false public
17
statements to hide negative results of clinical trials of its marquee drug. The Ninth Circuit
18
explained that the Amgen fiduciaries “knew or should have known that the Amgen Common
19
Stock Fund was purchasing stock at an artificially inflated price due to material
20
misrepresentations and omissions by company officers, . . . but they nevertheless continued
21
to allow plan participants to invest in the Fund.” Id. at *44. The court saw no tension
22
between ERISA and the reporting requirements imposed by securities laws because the
23
material misrepresentations were themselves violations of securities laws—in other words,
24
“the central problem in th[at] case is that Amgen officials, many of whom [we]re defendants
25
[t]here, made material representations and omissions in violation of the federal securities
26
laws”—and so both securities laws and the fiduciary obligations of ERISA “simultaneously”
27
28
5
2014).
This opinion amended and replaced a prior opinion, Harris v. Amgen, 770 F.3d 865 (9th Cir.
14
1
demanded that defendants publicly expose their own fraud. Id. at 48. “Any problem,” then,
2
“created by allowing plan participants to invest in the Fund as it purchased Amgen stock at
3
artificially inflated prices is a problem of the defendants’ own making.” Id. at 47.
But of course a company knows (or may be deemed to have known under appropriate
4
5
circumstances) that the company itself is perpetuating a fraud and cannot conceal its own
6
fraud from the market. Thus, when the Ninth Circuit stated that Amgen officials knew or
7
should have known that the stock was artificially inflated and had a duty to report this to the
8
market at that moment—a duty imposed by both ERISA and the securities laws—the court is
9
simply saying a fiduciary is not entitled to conceal his own fraud. See id.
Amgen, therefore, is missing the entire layer of a third-party fraud—here,
United States District Court
For the Northern District of California
10
11
Autonomy’s—that HP had to have understood in order to conceal. This brings us full-circle
12
to the entitlement to investigate that is so pressing here but absent from Amgen: even
13
assuming, as the Ninth Circuit did, that the decline in stock price triggered by disclosure
14
might be no more than that by which the stock was artificially inflated, id. at *46–47, this is
15
not so if a premature disclosure sparks market fears that thorough investigation later shows to
16
be unfounded. In that event, the decline could be far worse than what was actually
17
warranted, and a prudent fiduciary would not so act. Amgen itself states that “the proper
18
question is . . . whether the fiduciary used ‘appropriate methods’ to investigate the merits of
19
the transaction.” Id. at *42 (quoting Quan, 623 F.3d at 879). Here, HP conducted three
20
investigations in the process of integrating Autonomy and then commissioned the PwC
21
investigation of the fraud allegations after Whistleblower No. 4 came forward. HP should
22
have, and was entitled to, investigate, and none of the allegations in the SAC plausibly plead
23
otherwise. “Because the content of the duty of prudence turns on “the circumstances . . .
24
prevailing” at the time the fiduciary acts, § 1104(a)(1)(B), the appropriate inquiry will
25
necessarily be context specific.” 134 S. Ct. at 2471. The different context of this case than
26
the one at issue in Amgen justifies a different result.
27
IV.
28
CONCLUSION
For the foregoing reasons, the Court GRANTS the motion to dismiss. This is already
15
1
the Second Amended Complaint, and the Court sees no compelling representation that
2
changed facts or circumstances warrant another amendment. Rather, it is clear by this point
3
in the extensive life of this case that the SAC’s shortcomings are inherent legal ones, not
4
curable omissions of facts or inartful pleading that could be saved by amendment. See
5
Chang v. Chen, 80 F.3d 1293, 1296 (9th Cir. 1996). Plaintiffs’ “repeated failure to cure
6
deficiencies by amendments previously allowed” is a symptom of the SAC’s deeper
7
malaise—that the actions it sets forth are simply not actionable under Fifth Third and ERISA,
8
for the reasons explained above. See Foman v. Davis, 371 U.S. 178, 182 (1962).
9
Accordingly, any further amendment would be futile, and the Court hereby dismisses
United States District Court
For the Northern District of California
10
WITHOUT LEAVE TO AMEND.
11
IT IS SO ORDERED.
12
13
Dated: June 15, 2015
CHARLES R. BREYER
UNITED STATES DISTRICT JUDGE
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
16
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
Why Is My Information Online?